Piper Sandler Reiterates Overweight on DexCom, Raises Price Target to $95
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsReiterationPrice Target
Piper Sandler analyst Matt O'Brien reiterates DexCom (NASDAQ:DXCM) with a Overweight and raises the price target from $88 to $95.
Piper Sandler analyst Matt O'Brien reiterates DexCom (NASDAQ:DXCM) with a Overweight and raises the price target from $88 to $95.